Galecto Announces CEO Departure, Massive Dilution from Preferred Stock Conversion, and Share Authorization Increase
summarizeSummary
Galecto, Inc. announced the departure of its CEO, appointed an interim successor, and, most significantly, completed a preferred stock conversion that resulted in a massive increase in outstanding common shares, alongside an increase in authorized shares and approval for redomestication.
check_boxKey Events
-
Massive Dilution from Preferred Stock Conversion
The company converted 42,005 shares of Series C Preferred Stock into 42,005,000 common shares, increasing total outstanding common stock from approximately 1.6 million to 43.6 million. This represents over 2600% dilution.
-
CEO and President Departs
Hans T. Schambye ceased serving as CEO and President and resigned from the Board, effective February 10, 2026. He will receive separation benefits including full equity acceleration.
-
Interim Principal Executive Officer Appointed
Sherwin Sattarzadeh, the current Chief Operating Officer, was appointed interim principal executive officer, effective February 10, 2026.
-
Authorized Common Stock Increased
Stockholders approved an amendment to increase the number of authorized common shares from 300,000,000 to 500,000,000, effective February 9, 2026.
auto_awesomeAnalysis
This 8-K filing reveals several critical developments for Galecto, Inc. Most significantly, the company completed the conversion of 42,005 shares of Series C Preferred Stock into 42,005,000 shares of common stock, increasing the total outstanding common shares from approximately 1.6 million to 43.6 million. This represents an extraordinary level of dilution (over 2600%) that fundamentally alters the company's capital structure and will drastically reduce per-share value for existing shareholders. Concurrently, the company's CEO and President, Hans T. Schambye, has departed and resigned from the board, with the COO appointed as interim principal executive officer. The approval to increase authorized common stock from 300 million to 500 million further signals potential for future dilutive capital raises. These combined events indicate a period of significant corporate restructuring and financial re-engineering, posing substantial risks to current equity holders.
At the time of this filing, GLTO was trading at $23.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3M. The 52-week trading range was $2.01 to $38.33. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.